1 |
Aydemir H, Tuz HI, Piskin N, et al. Risk factors and clinical responses of pneumonia patients with colistin-resistant Acinetobacter baumannii-calcoaceticus [J]. World J Clin Cases, 2019, 7(10): 1111-1121.
|
2 |
Gao L, Lyu Y, Li Y. Trends in drug resistance of Acinetobacter baumannii over a 10-year period: nationwide data from the China surveillance of antimicrobial resistance program [J]. Chin Med J, 2017, 130(6): 659-664.
|
3 |
梁小英,农波.多重耐药鲍曼不动杆菌的耐药机制研究[J] 检验医学与临床, 2022, 19(11): 1566-1569.
|
4 |
Kadri SS, Adjemian J, Lai YL, et al. Difficult-to-treat resistance in Gram-negative Bacteremia at 173 US Hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents [J]. Clin Infect Dis, 2018, 67(12): 1803-1814.
|
5 |
Visalli MA, Murphy E, Projan SJ, et al. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis [J]. Antimicrob Agents Chemother (Bethesda), 2003, 47(2): 665-669.
|
6 |
宋淑萍,苏伟,郭丰,等.替加环素相关不良反应分析[J].中国继续医学教育, 2019, 11(26): 131-133.
|
7 |
陈佰义,何礼贤,胡必杰,等.中国鲍曼不动杆菌感染诊治与防控专家共识[J]中国医药科学, 2012, 2(8): 3-8.
|
8 |
Kaewpoowat Q, Ostrosky-Zeichner L. Tigecycline: a critical safety review [J]. Expert Opin Drug Saf, 2015, 14(2): 335-342.
|
9 |
Tasina E, Haidich AB, Kokkali S, et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis [J]. Lancet Infect Dis, 2011, 11(11): 834-844.
|
10 |
Lebowitz D, Müller CA, Balagué N, et al. Staphylococcus aureus versus Streptococcus pyogenes in hand infection [J]. Infect Dis (Lond), 2015, 47(10): 747-748.
|
11 |
Cui N, Cai H, Li Z, et al. Tigecycline-induced coagulopathy: a literature review[J]. Int J Clin Pharm, 2019, 41(6): 1408-1413.
|
12 |
Scott LJ. Eravacycline: a review in complicated intra-abdominal infections [J]. Drugs, 2019, 79(3): 315-324.
|
13 |
Zhanel GG, Baxter MR, Adam HJ, et al. In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015 [J]. Diagn Microbiol Infect Dis, 2018, 91(1): 55-62.
|
14 |
Alosaimy S, Abdul-Mutakabbir JC, Kebriaei R, et al. Evaluation of Eravacycline: a novel fluorocycline [J]. Pharmacotherapy, 2020, 40(3): 221-238.
|
15 |
Lee YR, Burton CE. Eravacycline, a newly approved fluorocycline [J]. Eur J Clin Microbiol Infect Dis, 2019, 38(10): 1787-1794.
|
16 |
Thakare R, Dasgupta A, Chopra S. Eravacycline for the treatment of patients with bacterial infections [J]. Drugs Today (Barc), 2018, 54(4): 245-254.
|
17 |
中华医学会外科学分会,中国研究型医院学会感染性疾病循证与转化专业委员会,中华外科杂志编辑部.外科常见腹腔感染多学科诊治专家共识[J].中华外科杂志, 2021, 59(3): 161-178.
|
18 |
Sy CL, Chen PY, Cheng CW, et al. Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms [J]. J Microbiol Immunol Infect, 2022, 55(3): 359-386.
|
19 |
Zeng M, Xia J, Zong Z, et al. Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli [J]. J Microbiol Immunol Infect, 2023, 56(4): 653-671.
|
20 |
Kong W, Deng T, Li S, et al. Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis [J]. BMC infectious diseases, 2023, 23(1): 256.
|
21 |
Solomkin J, Evans D, Slepavicius A, et al. Assessing the efficacy and safety of Eravacycline vs Ertapenem in complicated intra-abdominal infections in the investigating Gram-negative infections treated with Eravacycline (IGNITE 1) trial: a randomized clinical trial [J]. JAMA Surg, 2017, 152(3): 224-232.
|
22 |
Solomkin JS, Gardovskis J, Lawrence K, et al. IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of Eravacycline vs Meropenem in the treatment of complicated intraabdominal infections[J]. Clin Infect Dis, 2019, 69(6): 921-929.
|
23 |
Alosaimy S, Morrisette T, Lagnf AM, et al. Clinical outcomes of Eravacycline in patients treated predominately for Carbapenem-resistant Acinetobacter baumannii [J]. Microbiol Spectr, 2022, 10(5): e0047922.
|
24 |
Hobbs ALV, Gelfand MS, Cleveland KO, et al. A retrospective, multicentre evaluation of Eravacycline utilisation in community and academic hospitals [J]. J Glob Antimicrob Resist, 2022, 29: 430-433.
|